A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, 2-PERIOD, FIXED SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF [14C-PF-06700841] AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-06700841 IN HEALTHY MALE SUBJECTS USING A 14C-MICROTRACER APPROACH
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Brepocitinib (Primary) ; Brepocitinib (Primary)
- Indications Alopecia areata; Crohn's disease; Inflammatory bowel diseases; Plaque psoriasis; Ulcerative colitis; Vitiligo
- Focus Pharmacokinetics
- Sponsors Pfizer
- 05 Mar 2019 Status changed from recruiting to completed.
- 07 Jan 2019 Status changed from not yet recruiting to recruiting.
- 17 Dec 2018 New trial record